<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35129066</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1555-8576</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
              <Day>31</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer biology &amp; therapy</Title>
          <ISOAbbreviation>Cancer Biol Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Drugging the undruggable: activity-based protein profiling offers opportunities for targeting the KLK activome.</ArticleTitle>
        <Pagination>
          <StartPage>136</StartPage>
          <EndPage>138</EndPage>
          <MedlinePgn>136-138</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/15384047.2022.2033059</ELocationID>
        <Abstract>
          <AbstractText>The vast majority of the human proteome is yet to be functionally characterized thus hindering ongoing investigations on potential drug resistance mechanisms and advanced treatment options. Chemical proteomics is a powerful solution for enzyme profiling and the development of next generation cancer therapeutics previously deemed undruggable by small molecules. Within this field, activity-based protein profiling (ABPP) is a specialized technology capable of discriminating enzyme interactions that occur within complex, biological environments. In a recent publication by Lovell et al, the kallikrein-related peptidase (KLK) family of serine proteases that is highly implicated in the progression of prostate cancer (PCa) was subject to ABPP to elucidate enzymatic activities in the presence of enzalutamide. This is the first report of ABPP in PCa and of activity-based chemical probes selective for individual KLKs. Further, the study reveals androgen receptor-dependent activity among KLK proteins, particularly in mediating the invasion of the bone microenvironment.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Kristi Y</ForeName>
            <Initials>KY</Initials>
            <Identifier Source="ORCID">0000-0002-6228-4972</Identifier>
            <AffiliationInfo>
              <Affiliation>Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chau</LastName>
            <ForeName>Cindy H</ForeName>
            <Initials>CH</Initials>
            <AffiliationInfo>
              <Affiliation>Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Price</LastName>
            <ForeName>Douglas K</ForeName>
            <Initials>DK</Initials>
            <AffiliationInfo>
              <Affiliation>Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Figg</LastName>
            <ForeName>William D</ForeName>
            <Initials>WD</Initials>
            <Identifier Source="ORCID">0000-0003-2428-5613</Identifier>
            <AffiliationInfo>
              <Affiliation>Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>ZIA BC010453</GrantID>
            <Acronym>ImNIH</Acronym>
            <Agency>Intramural NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cancer Biol Ther</MedlineTA>
        <NlmUniqueID>101137842</NlmUniqueID>
        <ISSNLinking>1538-4047</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="D007610">Kallikreins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007610" MajorTopicYN="Y">Kallikreins</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011471" MajorTopicYN="Y">Prostatic Neoplasms</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">KLK activome</Keyword>
        <Keyword MajorTopicYN="Y">Prostate cancer</Keyword>
        <Keyword MajorTopicYN="Y">activity-based protein profiling</Keyword>
        <Keyword MajorTopicYN="Y">kallikrein</Keyword>
        <Keyword MajorTopicYN="Y">proteomics</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>7</Day>
          <Hour>8</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35129066</ArticleId>
        <ArticleId IdType="pmc">PMC8820805</ArticleId>
        <ArticleId IdType="doi">10.1080/15384047.2022.2033059</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Cravatt BF, Wright AT, Kozarich JW.. 
Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. Annu Rev Biochem. 2008;77:383–414. doi:10.1146/annurev.biochem.75.101304.124125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.biochem.75.101304.124125</ArticleId>
            <ArticleId IdType="pubmed">18366325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koomen DC, Meads MB, Magaletti DM, Guingab-Cagmat JD, Oliveira PS, Fang B, Liu M, Welsh EA, Meke LE, Jiang Z, et al. Metabolic changes are associated with melphalan resistance in multiple myeloma. J Proteome Res. 2021;20(6):3134–3149. doi:10.1021/acs.jproteome.1c00022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jproteome.1c00022</ArticleId>
            <ArticleId IdType="pubmed">34014671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi K-M, Cho E, Bang G, Lee S-J, Kim B, Kim J-H, Park S-G, Han EH, Chung Y-H, Kim JY, et al. Activity-based protein profiling reveals potential dasatinib targets in gastric cancer. Int J Mol Sci. 2020;21(23):E9276. doi:10.3390/ijms21239276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21239276</ArticleId>
            <ArticleId IdType="pmc">PMC7729964</ArticleId>
            <ArticleId IdType="pubmed">33291786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu -D-D, Zou C, Zhang J, Gao P, Zhu Y, Meng Y, Ma N, Lv M, Xu C, Lin Q, et al. Target profiling of an anticancer drug curcumin by an in situ chemical proteomics approach. Methods Mol Biol Clifton NJ. 2021;2213:147–161. doi:10.1007/978-1-0716-0954-5_13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-0716-0954-5_13</ArticleId>
            <ArticleId IdType="pubmed">33270200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng H, Lei Q, Wu Y, He Y, Li W. Activity-based protein profiling: recent advances in medicinal chemistry. Eur J Med Chem. 2020;191:112151. doi:10.1016/j.ejmech.2020.112151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2020.112151</ArticleId>
            <ArticleId IdType="pubmed">32109778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S, Tian Y, Wang M, Wang M, Sun G-B, Sun X-B. Advanced activity-based protein profiling application strategies for drug development. Front Pharmacol. 2018;9:353. doi:10.3389/fphar.2018.00353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2018.00353</ArticleId>
            <ArticleId IdType="pmc">PMC5900428</ArticleId>
            <ArticleId IdType="pubmed">29686618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lovell S, Zhang L, Kryza T, Neodo A, Bock N, De Vita E, Williams ED, Engelsberger E, Xu C, Bakker AT, et al. A suite of activity-based probes to dissect the KLK activome in drug-resistant prostate cancer. J Am Chem Soc. 2021;143(23):8911–8924. doi:10.1021/jacs.1c03950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jacs.1c03950</ArticleId>
            <ArticleId IdType="pubmed">34085829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michaelidou K, Kladi-Skandali A, Scorilas A. Kallikreins as biomarkers in human malignancies. In: Preedy VR, Patel VB, editors. Biomarkers in cancer. Springer (Netherlands): Dordrecht; 2014. p. 1–25. doi:10.1007/978-94-007-7744-6_18-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-94-007-7744-6_18-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heal WP, Dang THT, Tate EW. Activity-based probes: discovering new biology and new drug targets. Chem Soc Rev. 2011;40(1):246–257. doi:10.1039/c0cs00004c.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/c0cs00004c</ArticleId>
            <ArticleId IdType="pubmed">20886146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willems LI, Overkleeft HS, van Kasteren SI. Current developments in activity-based protein profiling. Bioconjug Chem. 2014;25(7):1181–1191. doi:10.1021/bc500208y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bc500208y</ArticleId>
            <ArticleId IdType="pubmed">24946272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weerapana E, Wang C, Simon GM, Richter F, Khare S, Dillon MBD, Bachovchin DA, Mowen K, Baker D, Cravatt BF. Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature. 2010;468(7325):790–795. doi:10.1038/nature09472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature09472</ArticleId>
            <ArticleId IdType="pmc">PMC3058684</ArticleId>
            <ArticleId IdType="pubmed">21085121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong Y, Loessner D, Irving-Rodgers H, Obermair A, Nicklin JL, Clements JA. Metastasis of ovarian cancer is mediated by Kallikrein related peptidases. Clin Exp Metastasis. 2014;31(1):135–147. doi:10.1007/s10585-013-9615-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10585-013-9615-4</ArticleId>
            <ArticleId IdType="pmc">PMC3892111</ArticleId>
            <ArticleId IdType="pubmed">24043563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong W, Liu Y, Seidl C, Dreyer T, Drecoll E, Kotzsch M, Bronger H, Dorn J, Magdolen V. Characterization of Kallikrein-related peptidase 4 (KLK4) MRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients. PloS One. 2019;14(2):e0212968. doi:10.1371/journal.pone.0212968.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0212968</ArticleId>
            <ArticleId IdType="pmc">PMC6392272</ArticleId>
            <ArticleId IdType="pubmed">30811511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ward CC, Kleinman JI, Brittain SM, Lee PS, Chung CYS, Kim K, Petri Y, Thomas JR, Tallarico JA, McKenna JM, et al. Covalent ligand screening uncovers a RNF4 E3 ligase recruiter for targeted protein degradation applications. ACS Chem Biol. 2019;14(11):2430–2440. doi:10.1021/acschembio.8b01083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acschembio.8b01083</ArticleId>
            <ArticleId IdType="pmc">PMC7422721</ArticleId>
            <ArticleId IdType="pubmed">31059647</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
